Tenders Are Invited For Licensing Spironolatone For Acne In Women

Nhs England Requires A Supplier To Apply For A Major (Type Ii) Mhra Marketing Authorisation Variation For Spironolactone. The Variation Is To Add A New Indication To The Current Licence (Marketing Authorisation) For Treating Acne In Women. The Successful Supplier Would Need To Prepare A Dossier For The Mhra Including A Risk Management Plan, Apply For The Licence Variation, And If Granted Update Their Licence, Summary Of Product Characteristics And Patient Information Leaflet With The New Indication And Related Data.≪Br/≫≪Br/≫To Register An Interest In Responding To This Opportunity And Obtain A Copy Of The Tender Documents Please Go To: Http://Health.Atamis.Co.Uk. All Communications And Request For Information Submissions Will Be Conducted Via Atamis. The Portal Can Be Accessed At Any Time Of The Day And It Is Free To Register.